Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The main complications of cirrhosis are ascites, esophageal varices and hepatic encephalopathy. About 30% to 70% patients with cirrhosis occur esophageal varices, and the most common complication is ascites. Somatostatin is used to treat esophageal for a long time, otherwise it could aslo prevent ascites. In the study, the investigators explore the effects of somatostatin on post-endoscopic portal hemodynamic in cirrhotic patients with esophageal gastric varices.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yunsheng Yang
• Treatments: Anti-Bacterial Agents; Somatostatin

Criteria

Inclusion Criteria:

• Cirrhosis with esophageal gastric varices needed endoscopic therapy

• Age 18-75 years

• Informed written consent

Exclusion Criteria:

• Use of vasoactive drugs 24 hours before endoscopic treatment

• Use of B-blocker within 1 week

• Previous surgical or endoscopic treatment for esophageal gastric varices

• Hepatic encephalopathy,comatose status and any other disease which could not accept endoscopic therapy

• Gastro-renal vein shunt

• Severe hepatic hydrothorax

• Hepatocellular carcinoma with portal vein thrombosis

• Severe coagulation disorders

• Severe active bacteria infection

• Severe cardiovascular disease, including a history of acute myocardial infarction,heart block, heart failure

• Severe renal function insufficiency （Calculated Creatinine Clearance Rate (Ccr) <30ml/min）

• Severe co-morbidity that would affect short-term prognosis

• Pregnancy or lactation

• Allergy to any ingredient of trial medication

• Medical or psychological condition that would not permit the patient to complete the study or sign the informed consent